Vimkunya is supplied as an injectable suspension; the vaccine is administered intramuscularly as a single 0.8mL dose.

Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...

Cataracts, dry eyes, glaucoma and other eye problems become more common with age. But these can be treated — and sometimes ...

Bavarian Nordic sets up a bout with Valneva’s Ixchiq, the former’s Vimkunya already having an edge in population reach.

Deadly viruses could become endemic in Europe unless urgent measures are taken, a leading expert has warned. Rising global ...

This week, for the first time in Ohio history, a man living a little more than an hour northwest of Dayton tested positive for bird flu.

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger ...

Bavarian Nordic (OTCPK:BVNRY) has received FDA approval for its vaccine Vimkunya for the prevention of chikungunya. The virus-like particle, or VLP, vaccine is approved for people aged 12 and older.

Some people may not develop any symptoms after contracting HIV and could remain undiagnosed until the symptoms of AIDS appear. This could be up to 10 years later. However, 50% or more of people living ...